Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Roger M. Phillips Review Article Open access 25 January 2016 Pages: 441 - 457
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities Dan LuTong LuAmita Joshi Review Article Open access 25 January 2016 Pages: 459 - 476
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma Carmen BelliLorenzo PiemontiMichele Reni Original Article 14 December 2015 Pages: 477 - 484
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer Mark StrohMichelle GreenJin Jin Original Article 12 January 2016 Pages: 485 - 494
Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors Viktor ArnholdJoachim BoosClaudia Lanvers-Kaminsky Original Article 19 January 2016 Pages: 495 - 505
Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma Chao ShangYan GuoYi-xue Xue Original Article 19 January 2016 Pages: 507 - 513
Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry James J. LeeJabed SerajJan Hendrik Beumer Original Article 19 January 2016 Pages: 515 - 526
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors Justine Yang BrucePatricia M. LoRussoGlenn Liu Original Article 20 January 2016 Pages: 527 - 538
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer Su Jin HeoInkyung JungByoung Chul Cho Original Article 25 January 2016 Pages: 539 - 548
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors Jason J. LukePatricia LoRussoJeffrey R. Infante Original Article 25 January 2016 Pages: 549 - 558
Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy Yusuke TakagiYukio HosomiTatsuru Okamura Original Article 28 January 2016 Pages: 559 - 564
Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer Hugh GiovinazzoParag KumarWilliam C. Zamboni Original Article 28 January 2016 Pages: 565 - 573
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer Rabih SaidYang YeApostolia-Maria Tsimberidou Original Article 29 January 2016 Pages: 575 - 581
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance Quan ZhangTianyu SunQunyou Tan Original Article 03 February 2016 Pages: 583 - 593
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer Hideki UenoMasafumi IkedaJunji Furuse Original Article 03 February 2016 Pages: 595 - 603
A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer Hyun-Jeong ShimKa-Rham KimSang-Hee Cho Original Article 05 February 2016 Pages: 605 - 612
Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription Pingjiang YeHaibo XingDa Li Original Article 05 February 2016 Pages: 613 - 621
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation Yasushi YoshimuraMitsue KurasawaNaoki Harada Original Article 05 February 2016 Pages: 623 - 628
UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy Ling ZhangXili CaoKun Tao Original Article 06 February 2016 Pages: 629 - 634
Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab Shruti AgrawalIan WaxmanRaymond Darbenzio Original Article 10 February 2016 Pages: 635 - 641
Phase I trial of nedaplatin chemotherapy concurrent with radiotherapy for untreated locoregionally advanced nasopharyngeal carcinoma Zibin LiangSiyang WangFeng Li Clinical Trial Report 30 January 2016 Pages: 643 - 651
The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy Alessia Dalla PriaMaggie BendleMark Bower Short Communication Open access 22 December 2015 Pages: 653 - 657
Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice Viviane Costa Junqueira RochaLuciana Souza de Aragão FrançaLain Carlos Pontes-de-Carvalho Short Communication 28 December 2015 Pages: 659 - 662